

State-by-State ADAP Profile

State	Financial Eligibility as % of FPL	Medical Eligibility (CD4=CD4 Cell Count, vl=Viral Load)	Protease Inhibitors Covered (6 Drugs Approved)	Non-nucleosides Covered (3 Drugs Approved)	OI Prophylaxis Covered (16 Drugs Recommended)	Other Medications Covered	Total FY 2000 Est. Budget (Federal/State Sources)	State \$ Contribution as % of Total Budget	ADAP Clients Served in June 2000	Emergency Cost-Containment Measures In Place as of September 2000
Alabama	250%	*	5	3	5	2	\$6,481,619	3%	596	Capped enrollment/waiting list
Alaska	300%		6 (5)	3	16 (0)	15 (0)	\$363,662	0%	26	
Arizona	300% (200%)		6 (5)	3	5	6	\$6,687,395	15% (20%)	677	
Arkansas	300%	*	6 (5)	3	9	19 (18)	\$2,350,012	0%	248	Capped enrollment/waiting list, capped/restricted access to PIs/antiretrovirals
California	400%		6 (5)	3	16 (12)	122 (90)	\$131,667,849	34%	12,693	
Colorado	185%		6 (5)	3	0	0	\$6,397,010	17% (20%)	663	
Connecticut	300%		6 (5)	3	15 (11)	54 (44)	\$9,519,518	6% (7%)	784	
Delaware	230%		6 (4)	3	12 (8)	38 (30)	\$2,133,666	0%	161	
D.C.	300%		5	3	13 (12)	28 (25)	\$9,100,340	4% (3%)	625	
Florida	350% (300%)		5	3	8	29 (10)	\$68,212,766	13%	10,500	
Georgia	300% (125%)	*	6 (5)	3	13 (0)	16 (0)	\$22,014,790	12% (10%)	2,312	
Hawaii	400%		6 (5)	3	16 (11)	30 (15)	\$2,121,873	25% (21%)	140	
Idaho	200%	CD4 <500	6 (4)	3	1	2	\$559,828	36% (31%)	85	Monthly/yearly per capita expenditure caps
Illinois	400%		5	3	16	35 (34)	\$23,990,143	30% (33%)	2,211	Capped/restricted access to PIs/antiretrovirals, monthly/yearly per capita expenditure caps
Indiana	300%		6 (5)	3	8 (6)	13 (47)	\$7,831,232	0%	292	
Iowa	200%		5	3	6	9 (6)	\$1,006,312	0%	128	
Kansas	300%		6 (5)	3	8	24 (18)	\$1,825,106	0%	366	
Kentucky	300%		5	3	5	9 (7)	\$3,200,000	3%	323	Capped enrollment/waiting list
Louisiana	200%		5	3	0	0	\$9,275,299	0%	1,538	
Maine	200%	CD4 <400 or vl >20k	6 (5)	3	6 (4)	4 (2)	\$654,110	9% (10%)	82	Capped/restricted access to PIs/antiretrovirals, transferred funds from other accounts
Maryland	400%		6 (5)	3	16	42 (30)	\$17,201,474	3% (4%)	1,284	
Massachusetts	<\$27,000 p.a.		6 (5)	3	10 (11)	63 (19)	\$12,838,436	16% (23%)	945	
Michigan	450% (362%)		6 (5)	3	13 (6)	37 (7)	\$7,773,145	0%	500	
Minnesota	300%		5	3	10	26 (25)	\$3,668,309	35% (7%)	328	
Mississippi	400%		6 (5)	3 (2)	9 (6)	10 (5)	\$5,426,959	14%	457	

Changes from the 2000 report are in bold. Data in *italics* are from 6/99. Shaded areas indicate restrictions lifted since the March 2000 report. All ADAPs covered all approved NRTIs at the time of this survey. *These ADAPs have medical criteria for access to ARV drugs. **The following classes of drugs are covered as groups: Antidepressants, Antilipidemia, Bipolar Medications, Oral Analgesics, Oral Antidiabetics, Topical Steroids.

State	Financial Eligibility as % of FPL	Medical Eligibility (CD4=CD4 Cell Count, vi=Viral Load)	Protease Inhibitors Covered (6 Drugs Approved)	Non-nucleosides Covered (3 Drugs Approved)	OI Prophylaxis Covered (16 Drugs Recommended)	Other Medications Covered	Total FY 2000 Est. Budget (Federal/State Sources)	State \$ Contribution as % of Total Budget	ADAP Clients Served In June 2000	Emergency Cost-Containment Measures In Place as of September 2000
Missouri	300%		5	3	13 (11)	235 (47)	\$8,143,296	27% (29%)	764	
Montana	300% (Need-based)		5	3	0	1	\$349,990	0%	38	Capped enrollment/waiting list
Nebraska	200%		6 (4)	3	10 (0)	66 (0)	\$919,249	16% (19%)	105	
Nevada	400%		5(4)	3	10(4)	23(10)	\$4,664,738	28%(30%)	529	
New Hampshire	300%		5	3	12	16 (17)	\$910,476	5% (0%)	101	
New Jersey	500%		6 (5)	3	16	43 (19)	\$33,713,926	5% (3%)	2,416	
New Mexico	300%		5	3	12	24 (20)	\$3,749,100	60% (62%)	293	
New York	<\$44,000 p.a		6 (5)	3	16	408 (371)	\$126,434,198	7% (5%)	10,824	
North Carolina	125%		5	3	11 (10)	22 (10)	\$12,381,432	39% (55%)	662	
North Dakota	150%		5	3	10	38 (37)	\$83,474	0%	14	
Ohio	281%		5	3	6	8 (6)	\$13,344,775	38% (41%)	1,260	Reduced ADAP formulary
Oklahoma	150%		5	3	6	3 (2)	\$3,820,365	21% (22%)	374	Capped/restricted access to PIs/antiretrovirals, monthly/yearly per capita expenditure caps
Oregon	325%		6 (5)	3	16	185 (175)	\$3,119,691	0% (2%)	334	
Pennsylvania	<\$30,000 p.a. certified as indigent		5	3	14	37 (38)	\$26,952,661	35% (38%)	1,941	
Puerto Rico		CD4 <500 or vi >10k	5	3	15	89 (79)	\$29,523,100	14% (23%)	2,625	
Rhode Island	400%		6 (5)	3	11	24 (9)	\$1,768,377	0%	220	
South Carolina	300%	CD4 <500	5	3	10 (7)	11	\$7,975,048	6% (8%)	746	Capped enrollment/waiting list
South Dakota	300%		0	3 (2)	7	21 (19)	\$155,000	0%	27	Capped enrollment/waiting list, monthly/yearly per capita expenditure caps
Tennessee	300%		5	3	10 (9)	15 (12)	\$6,469,509	0%	159	
Texas	200%		5	3	7	10 (4)	\$48,878,282	21% (26%)	5,501	Capped/restricted access to PIs/antiretrovirals
Utah	sliding scale		5	3	0	1	\$1,447,976	5% (9%)	123	
Vermont	200%		5	3	13 (12)	35 (18)	\$460,156	43%	56	
Virginia	250% (200%)		5	3	9	7 (6)	\$14,886,652	18% (9%)	1,320	
Washington	370%		6 (5)	3	11	49 (48) **	\$7,866,199	15% (2%)	717	
West Virginia	250%		5	3	2 (1)	5 (6)	\$1,113,626	9% (7%)	132	Lowered financial eligibility criteria, reduced ADAP formulary
Wisconsin	200%		5	3	10 (5)	9 (5)	\$2,955,551	14% (12%)	278	
Wyoming	300%		6 (5)	3	13	137 (42)	\$105,536	0%		

Changes from the 2000 report are in bold. Data in *italics* are from 6/99. Shaded areas indicate restrictions lifted since the March 2000 report. All ADAPs covered all approved NRTIs at the time of this survey. *These ADAPs have medical criteria for access to ARV drugs. **The following classes of drugs are covered as groups: Antidepressants, Antilipidemia, Bipolar Medications, Oral Analgesics, Oral Antidiabetics, Topical Steroids.